Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about ALLO: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| neurodegenerative_disorders | treats | disease | 0.80 |
| GABA-A_receptors | activates | protein | 0.80 |
| Alzheimer's_disease | treats | disease | 0.80 |
| depression | treats | disease | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| APOE4 association with TDP-43 pathology in AD | exploratory | Alzheimer's disease | 0.750 | 0.00 | human patients | proposed | N/A |
| E2F coordination of G2/M transcriptional program | exploratory | 0.750 | 0.00 | endocycling mammalian cells | proposed | N/A | |
| Microglial TREM2 Agonist In Vivo Efficacy | validation | Alzheimer's Disease | 0.450 | 0.50 | mouse | proposed | $360,000 |
| TREM2 Agonist Therapy for Parkinson's Disease — Experimental Design | validation | Parkinson's Disease | 0.450 | 0.50 | mouse | proposed | $280,000 |
| TREM2 Function in Alzheimer's Disease — From Risk Variant to Therapeut | validation | Alzheimer's Disease | 0.450 | 0.50 | human | proposed | $2,960,000 |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| s:** - GPR32 knockout in microglia should worsen neuroinflammation if | falsification | Neuroinflammation | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Synaptic pruning by microglia in ea | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $240,000 |
| DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| FTD Microglia Role: Protective vs Destructive Mechanism Study | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Microglial Aging and Immune Memory in Neurodegeneration — Training the | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Microglial Contributions to Huntington's Disease Pathogenesis | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] | Rusmini P, Cortese K, Crippa V, Cristofa | Autophagy | 2019 | 2 |
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via [PMID:37465997] | Chen X, He X, Xu F, Xu N, Sharifi NH, Zh | Stroke | 2023 | 1 |
| Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Ca [PMID:35642214] | Wang M, Pan W, Xu Y, Zhang J, Wan J, Jia | J Inflamm Res | 2022 | 1 |
| CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. [PMID:34492237] | Subbarayan MS, Joly-Amado A, Bickford PC | Pharmacol Ther | 2022 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Microglia in neurodegeneration. [PMID:30258234] | Hickman S, Izzy S, Sen P, Morsett L, El | Nat Neurosci | 2018 | 1 |
| How neuroinflammation contributes to neurodegeneration. [PMID:27540165] | Ransohoff RM | Science | 2016 | 1 |
| CX3CL1/CX3CR1 axis dysregulation contributes to epileptogenic mechanisms in foca [PMID:41863015] | Lei Lei; Shengyu Yang; Yinchao Li; Jiaha | Acta neuropathologica communic | 2026 | 0 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] | Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha | Frontiers in bioscience (Landm | 2026 | 0 |
| Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects [PMID:41924777] | Mroue-Ruiz FH, Desai B, Garvin MM, Shehu | Biochemical and biophysical re | 2026 | 0 |
| Systems-level molecular and immunological evidence identifies Th17/Treg modulati [PMID:41788408] | ["Li X", "Li X", "Chen S", "Wang L", "Xi | Frontiers in aging neuroscienc | 2026 | 0 |
| Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor- [PMID:41799205] | ["Wang S", "Wang Y", "Zhang Y", "Zhang Z | Theranostics | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning ALLO in their description or question text
Score: 0.600 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** The molecular basis for G3BP1-mediated stress granule formation centers on the in
Score: 0.563 · neurodegeneration · 2026-04-02
## Mechanistic Overview Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators starts from the claim t
Score: 0.532 · neurodegeneration · 2026-04-16
## Mechanistic Overview PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunctio
Score: 0.515 · unknown disease · 2026-04-26
Neuroinflammation triggers astrocyte and microglial MMP-9 activation, which proteolytically cleaves claudin-5, the princ
Score: 0.455 · drug-discovery · 2026-04-27
Allosteric modulators targeting cryptic sites in HSP90's C-terminal domain that are uniquely accessible when HSP90 is bo
Score: 0.000 · unknown disease · 2026-04-28
Identify allosteric sites distant from position 112 that can compensate for reduced lipid binding affinity caused by APO